The relationship between the phenotype of Parkinson's disease and levodopa-induced dyskinesia

Neuroscience Letters

Volumn 556, Issue , 2013, Pages 109-112

  Zhang, Yu han ^a   Tang, Bei sha ^a,b   Song, Chen yuan ^a   Xu, Qian ^a   Lou, Ming xin ^a   Liu, Zhen hua ^a   Yu, Ren he ^b   Yan, Xin xiang ^a,b   Guo, Ji feng ^a,b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Clinical phenotype; Levodopa induced dyskinesia; Parkinson's disease

Indexed keywords

AMANTADINE; ENTACAPONE; LEVODOPA; PIRIBEDIL; PRAMIPEXOLE; SELEGILINE;

ARTICLE; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; DYSKINESIA; HUMAN; MAJOR CLINICAL STUDY; PARKINSON DISEASE; PHENOTYPE; PRIORITY JOURNAL; RISK FACTOR; TREATMENT DURATION; UNIFIED PARKINSON DISEASE RATING SCALE;

CLINICAL PHENOTYPE; LEVODOPA-INDUCED DYSKINESIA; PARKINSON'S DISEASE;

ADULT; AGE OF ONSET; AGED; ANTIPARKINSON AGENTS; CROSS-SECTIONAL STUDIES; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; RISK FACTORS;

EID: 84887329726     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2013.10.018     Document Type: Article

References (25)

1. Reijnders J.S., Ehrt U., Lousberg R., Aarsland D., Leentjens A.F. The association between motor subtypes and psychopathologyin Parkinson's disease. Parkinsonism Relat. Disord. 2009, 15:379-382.
2. Rajput A.H., Sitte H.H., Rajput A., Fenton M.E., Pifl C., Hornykiewicz O. Globus pallidus dopamine and Parkinson motor subtypes: clinical and brain biochemical correlation. Neurology 2008, 70:1403-1410.
3. Rascol O., Brooks D.J., Korczyn A.D., De-Deyn P.P., Clarke C.E., Lang A.E. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa.056 study group. N. Engl. J. Med. 2000, 342:1484-1491.
4. Sharma J.C., Bachmann C.G., Linazasoro G. Classifying risk factors for dyskinesia in Parkinson's disease. Parkinsonism Relat. Disord. 2010, 16:490-497.
5. Hughes A.J., Daniel S.E., Kilford L., Lees A.J. Accuracy of clinical diagnosis of Parkinson's disease: a clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry 1992, 55:181-184.
6. Fahn S., Marsden C.D., Calne D.B., Goldstein M. Unified Parkinson's Disease Rating Scale 1987, 153-163. Macmillan, New Jersey.
7. Rajput A.H., Voll A., Rajput M.L., Robinson C.A., Rajput A. Course in Parkinson disease subtypes: a 39-year clinicopathologic study. Neurology 2009, 73:206-212.
8. Walker R.W., Howells A.R., Gray W.K. The effect of levodopa dose and body weight on dyskinesia in a prevalent population of people with Parkinson's disease. Parkinsonism Relat. Disord. 2011, 17:27-29.
9. Tomlinson C.L., Stowe R., Patel S., Rick C., Gray R., Clarke C.E. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov. Disord. 2010, 25:2649-2653.
10. Hauser R.A., McDermott M.P., Messing S. Factors associated with the development of motor fluctuations and dyskinesias in parkinson disease. Arch. Neurol. 2006, 63:1756-1760.
11. Kum W.F., Gao J., Durairajan S.S., Man S.C., Xie L.X., Lu J.H., Fong W.L., Li M. Risk factors in development of motor complications in Chinese patients with idiopathic Parkinson's disease. J. Clin. Neurosci. 2009, 16:1034-1037.
12. Zappia M., Annesi G., Nicoletti G., Arabia G., Annesi F., Messina D., Pugliese P., Spadafora P., Tarantino P., Carrideo S., Civitelli D., De-Marco E.V., Cirò-Candiano I.C., Gambardella A., Quattrone A. Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in parkinson disease: an exploratory study. Arch. Neurol. 2005, 62:601-605.
13. Van-Gerpen J.A., Kumar N., Bower J.H., Weigand S., Ahlskog J.E. Levodopa-associated dyskinesia risk among parkinson disease patients in Olmsted County, Minnesota, 1976-1990. Arch. Neurol. 2006, 63:205-209.
14. Ku S., Glass G.A. Age of Parkinson's disease onset as a predictor for the development of dyskinesia. Mov. Disord. 2010, 25:1177-1182.
15. Linazasoro G. New ideas on the origin of l-dopa-induced dyskinesias: age, genes and neural plasticity. Trends Pharmacol. Sci. 2005, 26:391-397.
16. Fahn S., Oakes D., Shoulson I., Kieburtz K., Rudolph A., Lang A., Olanow C.W., Tanner C., Marek K. Parkinson study group, levodopa and the progression of Parkinson's disease. N. Engl. J. Med. 2004, 351:2498-2508.
17. Kipfer S., Stephan M.A., Schüpbach W.M., Ballinari P., Kaelin-Lang A. Resting tremor in Parkinson disease: a negative predictor of levodopa-induced dyskinesia. Arch. Neurol. 2011, 68:1037-1039.
18. Jellinger K.A. Recent developments in the pathology of Parkinson's disease. J. Neural. Transm. Suppl. 2002, 62:347-376.
19. Eggers C., Kahraman D., Fink G.R., Schmidt M., Timmermann L. Akinetic-rigid and tremor-dominant Parkinson's disease patients show different patterns of FP-CIT single photon emission computed tomography. Mov. Disord. 2011, 26:416-423.
20. Rossi C., Frosini D., Volterrani D., De-Feo P., Unti E., Nicoletti V., Kiferle L., Bonuccelli U., Ceravolo R. Differences in nigro-striatal impairment in clinical variants of early Parkinson's disease: evidence from a FP-CIT SPECT study. Eur. J. Neurol. 2010, 17:626-630.
21. Eggers C., Pedrosa D.J., Kahraman D., Maier F., Lewis C.J., Fink G.R., Schmidt M., Timmermann L. Parkinson subtypes progress differently in clinical course and imaging pattern. PLoS ONE 2012, 7:1-8.
22. Alves G., Pedersen K.F., Bloem B.R., Blennow K., Zetterberg H., Borm G.F., Dalaker T.O., Beyer M.K., Aarsland D., Andreasson U., Lange J., Tysnes O.B., Zivadinov R., Larsen J.P. Cerebrospinal fluid amyloid-β and phenotypic heterogeneity in de novo Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 2013, 84:537-543.
23. Buongiorno M., Compta Y., Martí M.J. Amyloid-β and τ biomarkers in Parkinson's disease-dementia. J. Neurol. Sci. 2011, 310:25-30.
24. Van-Rooden S.M., Colas F., Martínez-Martín P., Visser M., Verbaan D., Marinus J., Chaudhuri R.K., Kok J.N., van-Hilten J.J. Clinical subtypes of Parkinson's disease. Mov. Disord. 2011, 26:51-58.
25. Marjama-Lyons J., Koller W. Tremor-predominant Parkinson's disease approaches to treatment. Drugs Aging 2000, 16:273-278.